Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research Hospital Medicinal…

Revive Confirms No Material Undisclosed Information

TORONTO, Aug. 12, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF)…

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for…

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed patients. Currently at 41…

Revive Therapeutics Approved to Trade on the OTCQB Market

TORONTO, June 25, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

TORONTO, June 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

TORONTO, June 08, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

TORONTO, April 27, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application

TORONTO, April 22, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, March 24, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV,…